阿那莫林实际用药疗效？

Anamorelin

As a new type of selective oral ghrelin receptor agonist, it has good clinical application prospects.

The ghrelin receptor has the same effect as ghrelin. It can promote the secretion of growth hormone, increase food intake, increase weight, increase muscle, increase appetite, increase metabolism, and improve tumor cachexia.

It is clinically used for patients with unresectable, progressive, recurrent, gastric cancer, pancreatic cancer, non-small cell lung cancer, and colorectal cancer with cancer cachexia.

Anamorelin is a ghrelin receptor agonist used to treat cancer cachexia. It promotes growth hormone secretion through growth hormone receptor activation, increases appetite, and thereby increases muscle mass and weight. Clinical trials of anamorelin have shown that patients' body mass index increased significantly and cachexia was improved.

anamoline

Background: Cachexia is primarily associated with weight loss and anorexia, which are common in patients with advanced cancer. Study to examine the efficacy and safety of anamorelin, a novel selective growth hormone receptor agonist, in Japanese patients with cancer cachexia.

Research methods: In a double-blind clinical trial, 174 patients with unresectable stage III/IV non-small cell lung cancer and cachexia were recruited in Japan, and were randomly assigned to the daily oral anamorelin (100 mg) group or the placebo group, and continued treatment for 12 weeks.

Study results: The mean least squared differences between LBM and basal levels in the anamorelin and placebo groups over 12 weeks were 1.38±0.18kg and -0.17±0.17kg, respectively. Changes in LBM, weight, and anorexia symptoms compared with baseline showed significant differences between the 2 treatment groups at all time points.

Anamorelin increases prealbumin at weeks 3 and 9, and 12 weeks of anamorelin treatment is safe and well tolerated in patients with non-small cell lung cancer.

Study conclusion: In Japanese patients with advanced non-small cell lung cancer, anamorelin significantly increased LBM, improved anorexia symptoms and nutritional status, but did not improve motor function. Since there are currently no effective treatments for cancer cachexia, anamorelin may be a beneficial treatment option. Anamorelin may be a treatment option for patients with cancer anorexia and cachexia.

Anamorelin improves cancer cachexia, reduces body weight and anorexia-related symptoms in patients with low body mass index, has long-term effects, is safe and well tolerated, and these effects can last up to 24 weeks.

Anamorelin usage and dosage

Adults take 100 mg once a day on an empty stomach and do not eat for 1 hour after taking it. If you do not gain weight or improve your appetite while taking anamorelin, you should stop taking the drug within 3 weeks of taking it.

References:

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4. PMID: 29205286; PMCID: PMC5814824.

Recommended related articles: